Stealth BioTherapeutic's SBT-272 improved mitochondrial motility in a murine model of amyotrophic lateral sclerosis.
List view / Grid view
Stealth BioTherapeutics expands Ocuvia’s clinical development into rare mitochondrial optic neuropathies
27 April 2015 | By Victoria White
Stealth BioTherapeutics has expanded its ophthalmology programme, led by Ocuvia, with FDA granting a Type B meeting for inherited optic neuropathies...